First, we discuss why Wall Street was less than convinced by Biogen's attempt to assuage concerns about its credibility. Then we explain an insider trading scandal that bridges biotech and elite-level soccer, the latest concerns over Wegovy, and the rest of the week's news in the life sciences. We also break some bittersweet news, with the help of some headline names from around biotech.